



FOR IMMEDIATE RELEASE

Contacts:

For Ohmx Corporation:

Dimitra Georganopoulou

Tel: (847) 491-8513

Fax: (847) 491-8510

dimitra@ohmx.com

Ohmx Announces the addition of Lauren Flanagan to the Team as Business Advisor.

Evanston IL, September 15th 2009 – Ohmx Corporation, a bioelectronic detection company focused on developing a near-patient analyzer for home monitoring of chronic diseases, is pleased to announce the addition of Lauren Flanagan to the team as a Business Advisor.

Lauren is a highly experienced business advisor and a successful entrepreneur that can provide direction and strategic solutions for the commercialization strategy and launch of Ohmx products. Some highlights of her eminent career are provided below:

Lauren Flanagan, Business Advisor brings 25 years experience in founding and operating technology companies to the Phenomenelle Angels Fund. Lauren also serves as SCIO Corp's CEO that provides strategic advisory and specialty investment banking services to emerging companies in the Biotech market sectors. SCIO assists clients with strategic planning, strategic partnerships, revenue growth, executive team/board development, restructuring and financing, and invests in select clients.

Recently, Lauren was honored to be part of Business Week's list of Top Tech Angels, where her investment track record was recognized.

For more information please see:

[The Top Angels in Tech, by Business Week.](#)

About the Company:

Ohmx is advancing e-Diagnostics by developing a home monitoring device that quantifies clinical biomarkers and other important disease indicators from the blood of a single finger prick. Ohmx's handheld monitoring device is electronic, low-cost, user-friendly, contains advanced communications protocols, and can be used as a near-patient analyzer in the convenience of the patient's home. Home monitoring of patient's health with Ohmx's devices will allow much more frequent transfer of information to healthcare providers and better healthcare for chronic disease patients than today's paradigm which require a visit to the doctor's office for blood testing.

This press release may contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.